ClinicalTrials.gg
WithdrawnNCT04711226Updated Aug 10, 2022

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

A Phase 2 interventional study of AT-1501 in Type 1 Diabetes Mellitus, sponsored by Anelixis Therapeutics, LLC. Withdrawn at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Anelixis Therapeutics, LLC · Phase 2, Interventional, and Treatment

Why this study was withdrawn
No participants enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 318 studies in Diabetes Mellitus, Type 1 with a site in Canada — 48 open to participants now, 61 under way, 15 of them phase 3. Diabetes Mellitus, Type 1 · Canada.

Enrollment
267th of 274
0 · median 45
Started
2021
with 17 others
Phase 2
59 of 318
5 open now
Registered
224th of 318
by date

Among the 318 studies in Diabetes Mellitus, Type 1 with a site in Canada, this one is the 267th largest by enrollment of the 274 interventional ones that give a count, is one of 18 that started in 2021, is one of 59 in phase 2, and was the 224th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

48 of the 318 studies in Diabetes Mellitus, Type 1 with a site in Canada are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Diabetes Mellitus, Type 1 with a site in Canada, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Read the detailed description

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant. This study will also provide valuable data with respect to its potential additional uses in autoimmunity and solid organ transplant. This is a single arm open-label study and up to 6 participants will be recruited at a single center in Canada.

The objectives include:

  • To assess the safety and tolerability of immunomodulation with AT-1501, in combination (AT+) with rabbit anti-thymoglobulin (ATG), etanercept and mycophenolate mofetil (MMF/EC-MPS) in adults with T1D undergoing islet cell transplant.
  • To assess the efficacy of immunomodulation with AT-1501 in adults with T1D undergoing islet cell transplant.

The duration of treatment may vary from participant to participant and could be up to 20 months. Participants may receive up to 2 islet cell transplants.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Type 1 Diabetes
  • T1D
  • Islet Cell Transplant
  • AT-1501
  • humanized blocking antibody to CD40L
  • CD40L inhibitor
  • monoclonal antibody
  • Glucose Metabolism Diseases
  • Diabetes Mellitus, Type 1
  • Endocrine System Diseases
  • Graft
  • Metabolic Diseases
  • Immune System Diseases
  • Autoimmune Diseases
  • Hypoglycemia
  • Hyperglycemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women 18-65 years of age
  2. A diagnosis of T1D ≥5 years with onset of disease at \<40 years of age
  3. Involvement in intensive diabetes management as directed by an endocrinologist or diabetologist with at least 3 clinical evaluations within the 12 months prior to Screening; using an insulin pump or multiple daily injection (MDI) insulin therapy; and, unable to achieve acceptable metabolic control because of the occurrence of severe hypoglycemia
  4. At least 2 unexplained SHEs not secondary to a missed meal or dosing error, etc., in the 12 months prior to Screening
  5. Glycosylated () level greater than 7% (53 mmol/mol) and less than 9.5% (80 mmol/mol) inclusive
  6. Absence of stimulated C peptide (\< 0.3 ng/mL) in response to a mixed meal tolerance test (MMTT) measured at 60 and 90 minutes after the start of consumption
  7. Reduced awareness of hypoglycemia as defined by a Clarke Score [Clarke 1995] of 4 or more at the time of Screening, during the Screening period and within the last 6 months prior to the transplant

Exclusion criteria

Exclusion Criteria:

  1. Any previous transplant
  2. level less than 7% (53 mmol/mol)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    AT-1501 Single Arm

    Drug: AT-1501

Interventions

06

What researchers measure

Primary outcomes

  1. Safety- Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)

    Incidence of adverse events

    Time frame: Accessed from date of transplant through 1 year post transplant for approximately 2 years

  2. Efficacy- Insulin independence

    Change in the proportion of participants that become insulin independent at Days 75 and 365 post-first, and final transplant

    Time frame: Days 75 , Day 365 post-first transplant, and final transplant and 1 year after discontinuation of AT-1501

Secondary outcomes

  1. Efficacy- Graft failure

    Proportion of participants with graft failure

    Time frame: Day 365

  2. Efficacy- Durability of insulin independence- long term

    Change in the proportion of participants that become insulin independent at year 2 and year 3

    Time frame: 2 and 3 years after discontinuation of AT- 1501

  3. Efficacy- HbA1c

    * Proportion of participants with HbA1c \<7.0% (53 mmol/mol) and free of serious hypoglycemic events (SHEs) * Proportion of participants with HbA1c ≤6.5% (48 mmol/mol) and free from SHEs

    Time frame: Day 365 and free of serious hypoglycemic events from Day 28 to 365 post-first transplant

Other outcomes

  1. Exploratory- Hypoglycemia unawareness (using the method of Clarke)

    Proportion of participants with hypoglycemia unawareness

    Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501

  2. Exploratory- Glycemic lability (using CGMS)

    Change in glycemic lability using CGMS- Continuous Glucose Monitoring System

    Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501

  3. Exploratory- Glycemic variability (using CGMS)

    Change in glycemic variability using CGMS- Continuous Glucose Monitoring System

    Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501

  4. Exploratory- Albumin excretion ratio (AER)

    Change in albumin excretion ratio (AER)

    Time frame: Day 365 post-first, and final transplant

  5. Exploratory- eGRF

    Change in eGRF

    Time frame: Day 365 post-first, and final transplant

  6. Exploratory- Macroalbuminemia

    Change in percent new macroalbuminemia

    Time frame: Day 365 post-first, and final transplant

  7. Exploratory- biomarkers of tissue damage and inflammation

    Biomarkers

    Time frame: Day -2, 3, 14, 28, 75, 175, 364

  8. Exploratory -Pharmacokinetic Parameters-AUC

    Pharmacokinetics (PK) of AT-1501

    Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.

  9. Exploratory- Pharmacokinetic Parameters-Cmax

    Pharmacokinetics (PK) of AT-1501

    Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.

  10. Exploratory- Pharmacokinetic Parameters-CL

    Pharmacokinetics (PK) of AT-1501

    Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.

  11. Exploratory- Pharmacokinetic Parameters- Vdss

    Pharmacokinetics (PK) of AT-1501

    Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.

  12. Exploratory- Pharmacokinetic Parameters- (t1/2)

    Pharmacokinetics (PK) of AT-1501

    Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.

07

Study locations

1 site
  • University of Alberta
    Edmonton, Alberta T6G 2E1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Jun 2024, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2021
First posted
Jan 15, 2021
StartActual
Feb 19, 2021
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2026
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04711226
Lead sponsor
Anelixis Therapeutics, LLC
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Feb 19, 2021
Primary completion
Jun 2024 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 10, 2022

Study contacts

Jeff Bornstein, MD
study chair · Eledon Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion